🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just in Nature Medicine👉Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC #prostatecancer👉enza + tala vs. enza, rPFS HR 0.44, OS trending strongly HR 0.69, efficacy in multiple HRR gene subsets⬇️open access👉tinyurl.com/wntrx75a OncoAlert PCF Science

Trends in Prostate Cancer Incidence and Mortality Rates Out on JAMA Network jamanetwork.com/journals/jaman… This cohort study analyzed #ProstateCancer incidence and mortality trends in California 🌅from 2004 to 2021, revealing a significant rise in distant-stage prostate cancer

Intravesical antibody drug Conjugates for #BladderCancer. Maria Jiang Princess Margaret Cancer Centre sits down with Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss how ADCs are transforming bladder cancer care and reshaping 1L treatment, boosting neoadjuvant response rates & even sparking bladder

📡 PSMA PET/CT vs. CT for 223Ra therapy in mCRPC? A new study finds PSMA PET/CT at baseline leads to longer OS (19.9 vs. 12.4 mos, p=0.038) & better patient selection by excluding soft tissue disease. Time to rethink imaging for 223Ra? #ReadMore on UroToday >

The FDA approved perioperative duvalumab with neoadjuvant chemo for muscle invasive bladder cancer today. It’s the only perioperative immune therapy trial with significant OS (0.75). Surgical safety was maintained. NCCN approval recently too #GUtrends25 fda.gov/drugs/resource…

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

🔥🚨OncoAlert Hot Off the Press #BigNews Press Release by Amgen 🧪🔬🧬 #DeLLphi304 trial of #IMDELLTRA (#TARLATAMAB) vs #Chemotherapy in 2nd line Tx for patients with #SmallCell #LungCancer shows: ✅Statistically Significant & Clinically Meaningful Improvement in #OverallSurvival

Today, #BCF25 is a full house with presentations by our esteemed international speakers Joshua Meeks with Molecular classification in NMIBC & Shilpa Gupta with Management of MIBC in cisplatin-ineligible patients with MIBC . Presentations will be on #UROpediaCanada soon. Peter Black

Congrats Girish Kulkarni Nimira Alimohamed on such a successful & amazing 6th Bladderca forum 🇨🇦 with an all ⭐️ faculty covering key basic/translational science & controversial clinical topics across the spectrum. Thanks for the invitation & warm hospitality!

IBCG European Urology Sia Daneshmand, M.D. Patrick Hensley, MD Neema Navai Janet Kukreja Wes Kassouf Jonathan Rosenberg MD UroToday.com Stephen B. Williams, MD, MBA, MS, FACHE Thomas Flaig Bladder Cancer Advocacy Network 🏛️ The backbone of bladder preservation is Trimodal Therapy (TMT): 🔹 Maximal TURBT 🔹 Radiation therapy 🔹 Concurrent chemo (cisplatin, 5-FU + MMC, gemcitabine, or carbogen + nicotinamide) TMT can offer survival outcomes on par with cystectomy for well select patients

Thank you ASCO daily news for the opportunity to share our (KSridhar) thoughts on NIAGARA: NAC + periop durva for #MIBC - impact on practice and what's ahead. One of the many exciting advances in bladder cancer! Matt Galsky Uromigos Tom Powles dailynews.ascopubs.org/do/niagara-per…

Why is there a difference in the pCR from NIAGARA at #ASCOGU25 Matt Galsky & #AUA25 Joshua Meeks (37% vs 42% for chemo/durva)? The 37% includes all ITT patients while the 42% only has surgery pts. Variability in pCR reporting is widespread making cross trial comparison hazardous.⚠️

.Maria Jiang reviewing critical updates in #prostatecancer care during our recent Best of ASCO GU & GI Cancers conference. Watch the full session here: ow.ly/Zq4V50VM4yY Catch up on all sessions from the conference here: ow.ly/lHNv50VM4yX

Just in case anyone missed this? prnewswire.com/news-releases/… UroToday.com Uromigos Bladder Cancer Advocacy Network

⚡️ On European Urology - European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines #BladderCancer europeanurology.com/article/S0302-…

Congrats #MichaelOng SOUMYAJIT ROY for oral Ab#5002 ASCO #ASCO25👉bit.ly/43NyyfY👉Real-world IRONMAN registry of mHSPC #prostatecancer (n=1288 pts)👉PSA<0.02 after 6-12 mo of Rx had best prognosis (3-yr OS 92.7%)👇Dan George OncoAlert UroToday.com PCF Science

#News: Phase III PSMAddition trial demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. go.novartis.social/4jzLY42

Congrats Michael Ong for the stellar talk ASCO #ASCO25 👉 PSA response (<0.2 ng/ml) after starting ADT+ARPI in mHSPC #prostatecancer (occurred in 50% of pts) associated with ⬆️OS (& 5-fold ⬆️ in death if PSA is >\=0.2). OncoAlert UroToday.com PCF Science Dan George

#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in The Lancet Oncology : thelancet.com/journals/lanon… 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣Very few

ctDNA can help guide adjuvant decision making in MIBC In pts with undetectable ctDNA after NAC + cystectomy, no definitive benefit for adjuvant ICB authors.elsevier.com/c/1lMET14kpm0h… Matt Galsky The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Uromigos Bladder Cancer Advocacy Network UroToday.com World Bladder Cancer Patient Coalition OncLive.com